Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain pseudogenes are non-coding remnants of formerly functional ADAM family genes. The ADAM (A Disintegrin and Metalloprotease) family consists of membrane-anchored proteins involved in processes such as cell adhesion, proteolysis, and signal transduction. However, ADAM pseudogenes, identified by the lack of conserved functional domains, are non-functional and do not encode active enzymes or receptors. They are not considered drug targets, do not participate directly in cellular processes, and have no known mechanisms of action or pharmacological relevance. The inclusion of "pseudogene" in the name means it is not a protein product, and the entry ENSG00000267793 lacks sufficient data to attribute specific aliases, functions, or relevance to disease or pharmacology[3][4][5][7]. If your interest is in the functional ADAM family proteins (such as ADAM10, ADAM17), those are proteases with multiple relevant biological and pathological roles[1][3]. However, for ENSG00000267793 and its generic "ADAM metallopeptidase domain pseudogene" label, it is not a drug target and carries no clinical or mechanistic significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain pseudogene.